Prevalence of SARS-CoV-2 Antibodies in Children and Adults with Type 1 Diabetes
Prevalence of SARS-CoV-2 Antibodies in Children and Adults with Type 1 Diabetes
复制标题
DOI：
10.1089/dia.2020.0609
复制
发表时间：
2021-02-25
影响因子：
5.4
通讯作者：
Yu, Liping
中科院分区：
文献类型：
--
作者：
Jia, Xiaofan;Gesualdo, Patricia;Yu, Liping
目的：由于糖尿病是COVID-19疾病严重症状、住院和死亡的风险因素，我们旨在评估严重急性呼吸综合征冠状病毒2的患病率2020年期间科罗拉多有和无1型糖尿病的儿童和成人中的SARS-CoV-2抗体。研究设计和方法：我们开发了一种高灵敏度和特异性的SARS-CoV-2抗体检测方法，并测量了儿童和成人新发（n = 129）和确诊的1型糖尿病（n = 94）患者的抗体。2020年1月至10月期间在我们中心接受常规糖尿病护理。在科罗拉多普通人群中检测了562名儿童和102名成人的抗体。结果：新发1型糖尿病患者中SARS-CoV-2抗体的患病率（0.8%; 95%置信区间0.1%-4.2%）或已确诊疾病的患者（4.3%; 1.7%-10.4%）与一般人群儿童（2.8%; 1.8%-4.6%）或成人（3.9%; 1.5%-9.7%）无差异。在抗体阳性的个体子集（n = 31）中，抗体保持阳性长达9个月，尽管感染后3个月开始下降（P = 0.007）结论：从2020年1月至10月，科罗拉多有和无1型糖尿病的儿童和成人中SARS-CoV-2抗体的患病率没有差异。我们没有发现新诊断的1型糖尿病青年中COVID-19感染患病率增加的证据。（COMIRB方案20-1007）
Objective: As diabetes is a risk factor for severe symptoms, hospitalization, and death with COVID-19 disease, we aimed to assess the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in children and adults with and without type 1 diabetes in Colorado during 2020.Research Design and Methods: We developed a highly sensitive and specific test for antibodies against SARS-CoV-2 and measured the antibodies in children and adults with new-onset (n = 129) and established type 1 diabetes (n = 94) seen for routine diabetes care at our center between January and October 2020. The antibodies were also measured in 562 children and 102 adults from the general population of Colorado.Results: The prevalence of SARS-CoV-2 antibodies in persons with new-onset type 1 diabetes (0.8%; 95% confidence interval 0.1%-4.2%) or those with established disease (4.3%; 1.7%-10.4%) did not differ from that in the general population children (2.8%; 1.8%-4.6%) or adults (3.9%; 1.5%-9.7%). In a subset of individuals with positive antibodies (n = 31), antibodies remained positive for up to 9 months, although the levels decreased starting 3 months after the infection (P = 0.007).Conclusions: From January to October 2020, the prevalence of SARS-CoV-2 antibodies were not different in children and adults with and without type 1 diabetes in Colorado. We found no evidence for increased prevalence of COVID-19 infections among youth with newly diagnosed type 1 diabetes. (COMIRB Protocol 20-1007)